IrAEPhase 2/3NCT06337695
Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer
A Phase 2/3 study testing Vedolizumab in people with IrAE and Immune-related Adverse Event, run by AHS Cancer Control Alberta at 2 sites in Canada.
Trial summary
The purpose of this study is to assess the prevention of immune checkpoint inhibitors (ICI) related diarrhea/colitis using vedolizumab in participants with unresectable stage III or metastatic stage IV cancer, starting standard of care (SOC) immunotherapy Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- IrAE, Immune-related Adverse Event, Diarrhea
- What is being tested?
- Vedolizumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 36 participants
- Where
- 2 sitesCanada
- Study dates
- 13 Aug 2026to 1 Dec 2030
- Phase
- Phase 2/3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Signed informed consent prior to initiation of any study specific activities or procedures
- Adult patient ≥18 years old
- Diagnosed with unresectable advanced stage III or metastatic stage IV malignant melanoma, lung, or renal cancer
- Planned for initiation of SOC treatment with any immunotherapy and develop an elevated fecal calprotectin > 100 μg/g within 4 weeks of first ICI dose
- Ability to and willingness to adhere to the randomized treatment interventions (vedolizumab or placebo), administered intravenously
- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test at the time of screening. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes.
- As per the Health Canada product monograph, WOCBP are strongly recommended to use adequate contraception to prevent pregnancy and to continue its use for at least 6 months after the last study visit.
- Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.
Who cannot join
- Condition(s) for which vedolizumab is contraindicated (e.g., hypersensitivity reaction, known allergic reaction to vedolizumab or its components)
- Current or prior use of vedolizumab
- Presence of inflammatory bowel disease (Crohn's disease, ulcerative colitis), indeterminate colitis, segmental colitis associated with diverticulosis or microscopic colitis
- Presence of ileostomy, colostomy, or short bowel syndrome
- Presence of known luminal gastrointestinal metastases at baseline
- Presence of significant pre-existing autoimmune disease (at investigator's discretion)
Show all 14Show fewer
- Presence of severe infection(s) or opportunistic infection(s)
- Active enteric infection with viral, bacterial, or parasitic pathogens
- Presence of untreated latent or active tuberculosis, or untreated chronic hepatitis B virus. If there is a clinical suspicion of either, it is at the discretion of the Investigator to order the appropriate work-up.
- Baseline ECOG status grade ≥3
- Pregnancy or lactation (no exclusion for pregnant partner)
- Treatment with another investigational product within 8 weeks of randomization
- Requirement for baseline anti-diarrheal treatment(s) (including but not limited to loperamide, diphenoxylate-atropine, octreotide, tincture of opium), anticholinergic drug(s), or opioid-based analgesic(s) used specifically for diarrhea control within 14 days of randomization
- Any condition or diagnosis, that could in the opinion of the Qualified Investigator or delegate interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study results, or put the participant at risk
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Michelle Kan contact
Canada2 sites, 2 recruiting
- Recruiting
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2
Michelle Kan, michelle.kan@cancercarealberta.ca
- Not yet recruiting
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
About this study
Official title: VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer: A Randomized, Double-Blinded, Placebo Controlled Trial
The purpose of this study is to assess the prevention of immune checkpoint inhibitors (ICI) related diarrhea/colitis using vedolizumab in participants with unresectable stage III or metastatic stage IV cancer, starting standard of care (SOC) immunotherapy
Read the detailed description
VERIFY is a multicenter, prospective, randomized, double-blinded, placebo-controlled, parallel group superiority trial, evaluating the efficacy and safety of vedolizumab, a monoclonal antibody targeting the α4β7 integrin receptor specific to gut-targeted T-lymphocytes, for the prevention of ICI-related diarrhea and colitis in participants with unresectable melanoma, lung, or renal cancer starting immunotherapy who are at high risk, defined by the development of an elevated fecal calprotectin >100 μg/g within 4 weeks of the first ICI dose.
Eligible participants will be randomized 1:1 to receive 6 months of vedolizumab or placebo, administered as prophylaxis therapy in addition to continuing ICI treatment (administered at weeks 0, 2, 6, 14, and 22). Participants will then be followed for 1 year.
- Conditions
- IrAE, Immune-related Adverse Event, Diarrhea, Colitis
- Being tested
- Vedolizumab, Placebo
- Keywords
- Immune Related Adverse Event, Immune Related diarrhea/colitis
- Medical subject headings
- Diarrhea, Colitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VedolizumabBiological
300 mg IV at weeks Baseline (Week 0) Weeks 2, 6, 14, and 22.
PlaceboBiological
300 mg IV at Baseline (Week 0) Weeks 2, 6, 14, and 22.
| Study group | Role | What they receive |
|---|---|---|
| Vedolizumab | Experimental | Participants receive 300 mg vedolizumab IV at Baseline (Week 0) Weeks 2, 6, 14, and 22. Receives: Biological: Vedolizumab |
| Placebo | Placebo comparator | Participants receive 300 mg placebo IV at Baseline (Week 0) Weeks 2, 6, 14, and 22. Receives: Biological: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
To establish the feasibility of the VERIFY protocol and determine progression to the full trial
Feasibility defined by achievement of all pre-specified progression criteria:
- Recruitment >75% target (>0.53 participants per site per month achieving randomization)
- Recruitment: fecal calprotectin after first dose of ICI therapy >100 μg/g in at least 15% of screened participants
- Protocol adherence: >95% of randomized participants receiving allocated treatment, protocol adherence in >90%
- Outcome data quality: endoscopy and biopsies taken in >90% of eligible participants, <10% loss to follow-up
- Feedback: no major concerns identified by patients or providers on acceptability survey
- >15% of placebo-treated participants developing the primary outcome (sufficient event rate for feasible prevention)
- Rate of PFS and OS is not lower than historical estimates from a similar population
Measured: Up to 5 years
Secondary outcomes (9)
To evaluate feasibility of recruitment
- Mean time to site initiation
Measured: Up to 5 years
To evaluate feasibility of recruitment
- Number of screened participants
Measured: Up to 5 years
To evaluate feasibility of recruitment
- Screen failure rate and qualitative assessment of reasons for screen failure
Measured: Up to 5 years
To evaluate feasibility of recruitment
- Qualitative assessment of reasons for screen failure
Measured: Up to 5 years
To evaluate feasibility of adhering to the protocol
Adherence feasibility metrics will include:
- Proportion of participants receiving the allocated treatment within 2 weeks of randomization
- Proportion of participants adhering to the follow-up schedule
Measured: Up to 5 years
To evaluate feasibility of adhering to the protocol
Adherence feasibility metrics will include:
- Number and qualitative description of minor and major protocol deviations
Measured: Up to 5 years
To evaluate feasibility of obtaining high quality outcome data
Outcome measure feasibility metrics will include:
- Proportion of eligible participants undergoing lower endoscopy and biopsies to confirm histologic ICI-related colitis
- Proportion of participants lost to follow-up and qualitative assessment of reasons for loss to follow-up
Measured: Up to 5 years
To evaluate the incidence of diarrhea and colitis in the placebo group
Feasibility of prevention metrics will include:
- Proportion of participants receiving placebo who develop CTCAE grade ≥2 diarrhea/colitis
- Proportion of participants receiving placebo who develop CTCAE grade ≥3 diarrhea/colitis
- Proportion of participants receiving placebo who develop CTCAE any grade diarrhea/colitis
Measured: Up to 1 year
To evaluate the efficacy of concomitant vedolizumab and ICI therapy
To ensure that there is no interaction between vedolizumab and efficacy of ICI therapy, evaluation will include:
- Progression free survival and overall survival in the vedolizumab group (compared to a historical control population)
Measured: Up to 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Mar 2024
- Study start13 Aug 2026
- Primary completion1 Dec 2030 (estimated)
- Study completion1 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for IrAEStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized, Double-Blinded, Placebo Controlled Trial, parallel group superiority trial
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AHS Cancer Control Alberta
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06337695
- Sponsor's protocol ID
- VERIFY (Pilot)
- Status last verified
- Aug 2026
- First submitted
- 22 Mar 2024
- Last updated
- 27 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer: A Randomized, Double-Blinded, Placebo Controlled Trial
- ClinicalTrials.gov ID
- NCT06337695
- Acronym / sponsor ID
- VERIFY (Pilot)
- Conditions
- IrAE, Immune-related Adverse Event, Diarrhea, Colitis
- Keywords
- Immune Related Adverse Event, Immune Related diarrhea/colitis
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- AHS Cancer Control AlbertaUniversity, hospital or other
- Study start
- 13 Aug 2026 (actual)
- Primary completion
- 1 Dec 2030 (estimated)
- Study completion
- 1 Dec 2030 (estimated)
- First posted
- 29 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to assess the prevention of immune checkpoint inhibitors (ICI) related diarrhea/colitis using vedolizumab in participants with unresectable stage III or metastatic stage IV cancer, starting standard of care (SOC) immunotherapy
Detailed description
VERIFY is a multicenter, prospective, randomized, double-blinded, placebo-controlled, parallel group superiority trial, evaluating the efficacy and safety of vedolizumab, a monoclonal antibody targeting the α4β7 integrin receptor specific to gut-targeted T-lymphocytes, for the prevention of ICI-related diarrhea and colitis in participants with unresectable melanoma, lung, or renal cancer starting immunotherapy who are at high risk, defined by the development of an elevated fecal calprotectin >100 μg/g within 4 weeks of the first ICI dose.
Eligible participants will be randomized 1:1 to receive 6 months of vedolizumab or placebo, administered as prophylaxis therapy in addition to continuing ICI treatment (administered at weeks 0, 2, 6, 14, and 22). Participants will then be followed for 1 year.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Randomized, Double-Blinded, Placebo Controlled Trial, parallel group superiority trial
| Arm | Type | Receives |
|---|---|---|
| Vedolizumab | Experimental | Biological: VedolizumabParticipants receive 300 mg vedolizumab IV at Baseline (Week 0) Weeks 2, 6, 14, and 22. |
| Placebo | Placebo comparator | Biological: PlaceboParticipants receive 300 mg placebo IV at Baseline (Week 0) Weeks 2, 6, 14, and 22. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Signed informed consent prior to initiation of any study specific activities or procedures
- Adult patient ≥18 years old
- Diagnosed with unresectable advanced stage III or metastatic stage IV malignant melanoma, lung, or renal cancer
- Planned for initiation of SOC treatment with any immunotherapy and develop an elevated fecal calprotectin > 100 μg/g within 4 weeks of first ICI dose
- Ability to and willingness to adhere to the randomized treatment interventions (vedolizumab or placebo), administered intravenously
Key exclusion criteria (14 listed)
- Condition(s) for which vedolizumab is contraindicated (e.g., hypersensitivity reaction, known allergic reaction to vedolizumab or its components)
- Current or prior use of vedolizumab
- Presence of inflammatory bowel disease (Crohn's disease, ulcerative colitis), indeterminate colitis, segmental colitis associated with diverticulosis or microscopic colitis
- Presence of ileostomy, colostomy, or short bowel syndrome
- Presence of known luminal gastrointestinal metastases at baseline
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vedolizumab300 mg IV at weeks Baseline (Week 0) Weeks 2, 6, 14, and 22. | Biological | Vedolizumab |
| Placebo300 mg IV at Baseline (Week 0) Weeks 2, 6, 14, and 22. | Biological | Placebo |
Primary outcome
To establish the feasibility of the VERIFY protocol and determine progression to the full trial
Time frame: Up to 5 years
Feasibility defined by achievement of all pre-specified progression criteria: * Recruitment >75% target (>0.53 participants per site per month achieving randomization) * Recruitment: fecal calprotectin after first dose of ICI therapy >100 μg/g in at least 15% of screened participants * Protocol adherence: >95% of randomized participants receiving allocated treatment, protocol adherence in >90% * Outcome data quality: endoscopy and biopsies taken in >90% of eligible participants, <10% loss to follow-up * Feedback: no major concerns identified by patients or providers on acceptability survey * >15% of placebo-treated participants developing the primary outcome (sufficient event rate for feasible prevention) * Rate of PFS and OS is not lower than historical estimates from a similar population
9 secondary outcomes
To evaluate feasibility of recruitment
Time frame: Up to 5 years
To evaluate feasibility of recruitment
Time frame: Up to 5 years
To evaluate feasibility of recruitment
Time frame: Up to 5 years
To evaluate feasibility of recruitment
Time frame: Up to 5 years
To evaluate feasibility of adhering to the protocol
Time frame: Up to 5 years
To evaluate feasibility of adhering to the protocol
Time frame: Up to 5 years
To evaluate feasibility of obtaining high quality outcome data
Time frame: Up to 5 years
To evaluate the incidence of diarrhea and colitis in the placebo group
Time frame: Up to 1 year
To evaluate the efficacy of concomitant vedolizumab and ICI therapy
Time frame: Up to 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for IrAE
RecruitingPhase 2
Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)
Immune-related Adverse Event, Diarrhea
Active, not recruitingPhase 2
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
Melanoma Stage III, Melanoma Stage IV
RecruitingPhase 1
Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events
Immune-Related Adverse Events
RecruitingPhase 2
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
RecruitingPhase 2
Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy
Immune-mediated Hepatitis, Immune-related Adverse Event
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Michelle Kan contact
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Vedolizumab in people with IrAE and Immune-related Adverse Event, run by AHS Cancer Control Alberta at 2 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Christopher Ma, MD (403-592-5013, christopher.ma@ucalgary.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To establish the feasibility of the VERIFY protocol and determine progression to the full trial (time frame: Up to 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2026.